Predictive Factors of Bladder Tumor Recurrence after Nephro-Ureterectomy for Urothelial Carcinoma


Objectives: To evaluate the incidence of bladder cancer after nephro-ureterectomy (NUT) and determine the potential risk factors of bladder recurrence in patients with upper urinary tract urothelial carcinoma (UUT-UC). Materials and Methods: We retrospectively assessed 37 patients with UUT-UC including a significant follow-up after NUT of 34 months (range 12 - 120 months). The median age of the population was 72 years (range 48 - 83 years). Patients with a previous history of bladder cancer, concomitant diagnosis of bladder tumor and UUT-UC; or a metastatic UUT-UC were excluded from the study. Results: Out of these 37 patients, 17 presented a bladder recurrence within an average time of 12 months (range 3 to 31 months) after the NUT. In 94% of the cases, bladder recurrence occurred within the first 24 months following the NUT. Histological distribution was: 13 Ta tumors (76%), 2 pT1 tumors (11.7%); 11 patients had a high stage lesion (76%), whereas 4 patients had a low stage lesion (23.5%). As regards the anatomo-pathological characteristics of the UUT-UC, the supra iliac localization of the tumor is a significant risk factor of bladder recurrence (p = 0.04). Conclusion: Bladder recurrence after NUT occurred frequently and could have possibly been under-estimated. The use of intra-vesical instillation of Mitomycin C after NUT has been recently recommended by the European Association of Urology, but no predictive factors have yet been identified. Early diagnosis of bladder recurrence could certainly have reduced mortality in this patient population.

Share and Cite:

Rebibo, J. , Lacarrière, E. , Nouhaud, F. , Safsaf, A. , Caremel, R. and Pfister, C. (2015) Predictive Factors of Bladder Tumor Recurrence after Nephro-Ureterectomy for Urothelial Carcinoma. Journal of Cancer Therapy, 6, 122-128. doi: 10.4236/jct.2015.62013.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J. and Thun, M.J. (2009) Cancer Statistics, 2009. CA: A Cancer Journal for Clinicians, 59, 225-249.
[2] Roupret, M., Wallerand, H., Traxer, O., Roy, C., Mazerolles, C., Saint, F., et al. (2010) Check up and Management of Upper Urinary Tract Tumors in 2010: An Update from the Committee of Cancer from the French National Association of Urology. Progres en Urologie, 20, 260-271.
[3] Pfister, C., Roupret, M., Wallerand, H., Davin, J.L., Quintens, H., Guy, L., et al., Oncology Committee of the French Association of Urology (CCAFU) (2010) Recommendations Onco-Urology 2010: Urothelial Tumors. Progres en Urologie, 20, S255-S274.
[4] Messing, E.M. and Catalona, W. (1998) Urothelial Tumors of the Urinary Tract. In: Walsh, P.C., Retik, A.B., Vaughan, E.D. and Wein, A.J., Eds., Campbell’s Urology, WB Saunders, Philadelphia, 2327-2410.
[5] Mullerad, M., Russo, P., Golijanin, D., Chen, H.N., Tsai, H.H., Donat, S.M., et al. (2004) Bladder Cancer as a Prognostic Factor for Upper Tract Transitional Cell Carcinoma. Journal of Urology, 172, 2177-2181.
[6] Kirkali, Z. (2003) Transitional Cell Carcinoma of the Ureter and Renal Pelvis. Critical Reviews in Oncology/Hematology, 47, 155-169.
[7] Hisataki, T., Miyao, N., Masumori, N., Takahashi, A., Sasai, M., Yanase, M., et al. (2000) Risk Factors for the Development of Bladder Cancer after Upper Tract Urothelial Cancer. Urology, 55, 663-667.
[8] Kang, C.H., Yu, T.J., Hsieh, H.H., Yang, J.W., Shu, K., Huang, C.C., et al. (2003) The Development of Bladder Tumors and Contralateral Upper Urinary Tract Tumors after Primary Transitional Cell Carcinoma of the Upper Urinary Tract. Cancer, 98, 1620-1626.
[9] Lughezzani, G., Burger, M., Margulis, V., Matin, S.F., Novara, G., Roupret, M., et al. (2012) Prognostic Factors in Upper Urinary Tract Urothelial Carcinomas: A Comprehensive Review of the Current Literature. European Urology, 62, 100-114.
[10] Terakawa, T., Miyake, H., Muramaki, M., Takenaka, A., Hara, I. and Fujisawa, M. (2008) Risk Factors for Intravesical Recurrence after Surgical Management of Transitional Cell Carcinoma of the Upper Urinary Tract. Urology, 71, 123-127.
[11] Milojevic, B., Djokic, M., Sipetic-Grujicic, S., Milenkovic-Petronic, D., Vuksanovic, A., Dragicevic, D., et al. (2011) Bladder Cancer after Managing Upper Urinary Tract Transitional Cell Carcinoma: Risk Factors and Survival. International Urology and Nephrology, 43, 729-735.
[12] Huang, W.W., Huang, H.Y., Liao, A.C., Shiue, Y.L., Tai, H.L., Lin, C.M., et al. (2009) Primary Urothelial Carcinoma of the Upper Tract: Important Clinicopathological Factors Predicting Bladder Recurrence after Surgical Resection. Pathology International, 59, 642-649.
[13] Zigeuner, R.E., Hutterer, G., Chromecki, T., Rehak, P. and Langner, C. (2006) Bladder Tumour Development after Urothelial Carcinoma of the Upper Urinary Tract Is Related to Primary Tumour Location. BJU International, 98, 1181-1186.
[14] Hirano, D., Okada, Y., Nagane, Y., Satoh, K., Mochida, J., Yamanaka, Y., et al. (2012) Intravesical Recurrence after Surgical Management of Urothelial Carcinoma of the Upper Urinary Tract. Urology International, 89, 71-77.
[15] Xylinas, E., Colin, P., Audenet, F., Phe, V., Cormier, L., Cussenot, O., et al. (2013) Intravesical Recurrence after Radical Nephro-Ureterectomy for Upper Tract Urothelial Carcinomas: Predictors and Impact on Subsequent Oncological Outcomes from a National Multicenter Study. World Journal of Urology, 31, 61-68.
[16] Pignot, G., Colin, P., Zerbib, M., Audenet, F., Soulie, M., Hurel, S., et al. (2013) For the French Collaboration National Database on UUT-UC. World Journal of Urology.
[17] Sylvester, R.J., Oosterlinck, W. and van der Meijden, A.P. (2004) A Single Immediate Postoperative Instillation of Chemotherapy Decreases the Risk of Recurrence in Patients with Stage Ta T1 Bladder Cancer: A Meta-Analysis of Published Results of Randomized Clinical Trials. Journal of Urology, 171, 2186-2190.
[18] O’Brien, T., Ray, E., Singh, R., Coker, B. and Beard, R., British Association of Urological Surgeons Section of Oncology (2011) Prevention of Bladder Tumours after Nephro-Ureterectomy for Primary Upper Urinary Tract Urothelial Carcinoma: A Prospective, Multicentre, Randomised Clinical Trial of a Single Postoperative Intravesical Dose of Mitomycin C (the ODMIT-C Trial). European Urology, 60, 703-710.
[19] Roupret, M., Babjuk, M., Comperat, E., Zigeuner, R., Sylvester, R., Burger, M., et al. (2013) European Guidelines on Upper Tract Urothelial Carcinomas: 2013 Update. European Urology, 63, 1059-1071.
[20] Fradet, Y., Grossman, H.B., Gomella, L., Lerner, S., Cookson, M., Albala, D., et al., PC B302/01 Study Group (2007) A Comparison of Hexaminolevulinate Fluorescence Cystoscopy and White Light Cystoscopy for the Detection of Carcinoma in Situ in Patients with Bladder Cancer: A Phase III, Multicenter Study. Journal of Urology, 178, 68-73.
[21] Burger, M., Grossman, H.B., Droller, M., Schmidbauer, J., Hermann, G., Dragoescu, O., et al. (2013) Photodynamic Diagnosis of Non-Muscle-Invasive Bladder Cancer with Hexaminolevulinate Cystoscopy: A Meta-Analysis of Detection and Recurrence Based on Raw Data. European Urology, 2838, 353-359.
[22] Rink, M., Sjoberg, D., Comploj, E., Margulis, V., Xylinas, E. and Lee, R.K. (2012) Risk of Cancer-Specific Mortality Following Recurrence after Radical Nephro-Ureterectomy. Annals of Surgical Oncology, 19, 4337-4344.

Copyright © 2022 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.